NASDAQ:AVXS - AveXis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$217.83
+0.30 (1.20%)
Get New AveXis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVXS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for AveXis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $217.83.

This chart shows the closing price for AVXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in AveXis. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2018Jefferies Financial GroupDowngradeBuy ➝ HoldLow
4/13/2018Chardan CapitalDowngradeBuy ➝ NeutralLow
4/12/2018BarclaysDowngradeOverweight ➝ Equal Weight$152.00Low
4/12/2018UBS GroupDowngradeBuy ➝ NeutralLow
4/11/2018Credit Suisse GroupReiterated RatingOutperform ➝ Neutral$139.00Low
4/10/2018CitigroupDowngradeBuy ➝ NeutralLow
4/9/2018Nomura SecuritiesUpgradeReduce ➝ NeutralLow
4/9/2018Morgan StanleyDowngradeOverweight ➝ HoldN/A
4/9/2018Credit Suisse GroupBoost Price TargetOutperform$139.00 ➝ $170.00N/A
4/9/2018MizuhoDowngradeBuy ➝ NeutralN/A
4/9/2018William BlairInitiated CoverageOutperform ➝ HoldN/A
3/14/2018MizuhoSet Price TargetBuy$147.00High
3/13/2018William BlairReiterated RatingBuyLow
3/6/2018Morgan StanleySet Price TargetOverweight ➝ Buy$119.00 ➝ $129.00Medium
3/3/2018William BlairReiterated RatingBuyLow
3/1/2018Jefferies Financial GroupReiterated RatingBuy$141.00High
2/28/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$150.00 ➝ $148.00Medium
2/28/2018Canaccord GenuitySet Price TargetHold ➝ Hold$110.00 ➝ $120.00Low
2/28/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$134.00 ➝ $139.00Low
2/28/2018Wells Fargo & CompanyReiterated RatingOutperform$134.00 ➝ $171.00Low
2/28/2018UBS GroupSet Price TargetBuy$122.00 ➝ $143.00Low
2/20/2018Sanford C. BernsteinReiterated RatingOutperform$110.00 ➝ $144.00High
2/12/2018MizuhoInitiated CoverageBuy ➝ Buy$147.00Medium
2/9/2018BarclaysBoost Price TargetOverweight ➝ Overweight$124.00 ➝ $152.00Medium
1/30/2018William BlairReiterated RatingBuyLow
1/18/2018BMO Capital MarketsReiterated RatingBuy$150.00High
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$134.00High
1/9/2018Royal Bank of CanadaReiterated RatingHold$92.00Medium
1/8/2018BMO Capital MarketsReiterated RatingBuyN/A
1/5/2018Canaccord GenuitySet Price TargetHold$110.00High
1/5/2018Chardan CapitalReiterated RatingBuy$135.00High
1/5/2018Morgan StanleySet Price TargetBuy$120.00High
1/5/2018UBS GroupSet Price TargetBuy$122.00High
1/5/2018CitigroupSet Price TargetPositive ➝ Buy$132.00High
12/20/2017Canaccord GenuitySet Price TargetHold$110.00Medium
12/14/2017Canaccord GenuitySet Price TargetHold$110.00Low
11/10/2017Bank of AmericaLower Price TargetBuy$115.00 ➝ $112.00N/A
11/10/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$92.00 ➝ $97.00N/A
11/2/2017Royal Bank of CanadaReiterated RatingHold$92.00N/A
11/2/2017Chardan CapitalReiterated RatingBuyN/A
10/26/2017Canaccord GenuityInitiated CoverageHold ➝ Hold$110.00N/A
10/12/2017BMO Capital MarketsReiterated RatingOutperform$123.00 ➝ $130.00N/A
10/12/2017Jefferies Financial GroupBoost Price TargetBuy$118.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$130.00N/A
10/3/2017UBS GroupReiterated RatingBuy$95.00 ➝ $122.00High
10/2/2017CitigroupBoost Price TargetBuy$100.00 ➝ $116.00Low
9/30/2017BMO Capital MarketsReiterated RatingOutperform$123.00Low
9/29/2017Wells Fargo & CompanyReiterated RatingOutperformHigh
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$92.00High
9/6/2017BarclaysInitiated CoverageOverweight$124.00Low
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform$89.00 ➝ $134.00Low
8/29/2017Nomura InstinetInitiated CoverageReduce ➝ Reduce$52.00Low
8/28/2017Nomura SecuritiesInitiated CoverageReduce$52.00High
8/23/2017William BlairInitiated CoverageOutperform ➝ Outperform$107.00Medium
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$120.00Medium
8/11/2017Jefferies Financial GroupReiterated RatingBuy$92.00 ➝ $108.00Low
8/11/2017Chardan CapitalReiterated RatingBuy ➝ Buy$102.50 ➝ $130.00Medium
8/11/2017BMO Capital MarketsReiterated RatingBuy$123.00Medium
8/9/2017Morgan StanleyReiterated RatingOverweight$118.00Low
8/3/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$118.00Low
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$108.00Medium
6/28/2017Jefferies Financial GroupReiterated RatingBuyHigh
6/18/2017Chardan CapitalSet Price TargetBuy$103.00Low
6/16/2017BMO Capital MarketsReiterated RatingOutperform$95.00High
6/15/2017CitigroupSet Price TargetBuy$90.00 ➝ $100.00Low
5/25/2017Jefferies Financial GroupReiterated RatingBuy$92.00High
5/23/2017CitigroupInitiated CoverageBuy$90.00High
4/19/2017Jefferies Financial GroupReiterated RatingBuy$92.00Medium
3/29/2017UBS GroupInitiated CoverageBuy ➝ Buy$95.00N/A
3/17/2017Chardan CapitalReiterated RatingBuy$100.00Medium
3/17/2017Jefferies Financial GroupBoost Price TargetBuy$79.00 ➝ $92.00High
3/17/2017The Goldman Sachs GroupBoost Price TargetBuy$91.00 ➝ $108.00High
3/17/2017BMO Capital MarketsReiterated RatingOutperform$85.00 ➝ $95.00High
2/7/2017Chardan CapitalReiterated RatingBuy$85.00 ➝ $100.00N/A
1/26/2017Chardan CapitalBoost Price TargetBuy$85.00 ➝ $100.00N/A
12/29/2016BMO Capital MarketsReiterated RatingOutperform$85.00N/A
12/25/2016Chardan CapitalSet Price TargetBuy$85.00N/A
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2021

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
AveXis logo
AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.
Read More

Today's Range

Now: $217.83
Low: $217.83
High: $217.83

50 Day Range

MA: N/A

52 Week Range

Now: $217.83
Low: $65.54
High: $217.94

Volume

222 shs

Average Volume

816,305 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AveXis?

The following Wall Street analysts have issued stock ratings on AveXis in the last twelve months:
View the latest analyst ratings for AVXS.

What is the current price target for AveXis?

0 Wall Street analysts have set twelve-month price targets for AveXis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for AveXis in the next year.
View the latest price targets for AVXS.

What is the current consensus analyst rating for AveXis?

AveXis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AVXS.

What other companies compete with AveXis?

How do I contact AveXis' investor relations team?

AveXis' physical mailing address is 2275 HALF DAY ROAD SUIT 200, BANNOCKBURN IL, 60015. The company's listed phone number is 847-572-8280 and its investor relations email address is [email protected] The official website for AveXis is www.avexis.com.